Comparative study reveals neoadjuvant chemoradiotherapy improves survival in stage IIIA N2 lung cancer, indicating its effectiveness over other treatments.
Key Points
Neoadjuvant chemoradiotherapy resulted in the highest recurrence-free survival rates among treatment options.
Five-year overall survival was 30.1% after chemoradiotherapy, 12.3% after chemotherapy, and 6.3% after chemotherapy plus adjuvant radiotherapy.
The study evaluated various treatment regimens in 306 patients, measuring long-term outcomes and responses.
Neoadjuvant chemoradiotherapy reduced the need for pneumonectomies compared to other treatment methods.